Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 177

1.

Threonine Tyrosine Kinase Inhibition Eliminates Lung Cancers by Augmenting Apoptosis and Polyploidy.

Zheng L, Chen Z, Kawakami M, Chen Y, Roszik J, Mustachio LM, Kurie JM, Villalobos P, Lu W, Behren C, Mino B, Solis LM, Silvester J, Thu KL, Cescon DW, Rodriguez-Canales J, Wistuba II, Mak TW, Liu X, Dmitrovsky E.

Mol Cancer Ther. 2019 Jul 29. pii: molcanther.0864.2018. doi: 10.1158/1535-7163.MCT-18-0864. [Epub ahead of print]

PMID:
31358662
2.

Reply to Oegema et al.: CFI-400945 and Polo-like kinase 4 inhibition.

Kawakami M, Mustachio LM, Zheng L, Chen Y, Rodriguez-Canales J, Mino B, Kurie JM, Roszik J, Villalobos PA, Thu KL, Silvester J, Cescon DW, Wistuba II, Mak TW, Liu X, Dmitrovsky E.

Proc Natl Acad Sci U S A. 2018 Nov 13;115(46):E10810-E10811. doi: 10.1073/pnas.1813967115. Epub 2018 Oct 30. No abstract available.

3.

New Cell Cycle Inhibitors Target Aneuploidy in Cancer Therapy.

Kawakami M, Liu X, Dmitrovsky E.

Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:361-377. doi: 10.1146/annurev-pharmtox-010818-021649. Epub 2018 Aug 15.

PMID:
30110577
4.

CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade.

Chen L, Diao L, Yang Y, Yi X, Rodriguez BL, Li Y, Villalobos PA, Cascone T, Liu X, Tan L, Lorenzi PL, Huang A, Zhao Q, Peng D, Fradette JJ, Peng DH, Ungewiss C, Roybal J, Tong P, Oba J, Skoulidis F, Peng W, Carter BW, Gay CM, Fan Y, Class CA, Zhu J, Rodriguez-Canales J, Kawakami M, Byers LA, Woodman SE, Papadimitrakopoulou VA, Dmitrovsky E, Wang J, Ullrich SE, Wistuba II, Heymach JV, Qin FX, Gibbons DL.

Cancer Discov. 2018 Sep;8(9):1156-1175. doi: 10.1158/2159-8290.CD-17-1033. Epub 2018 Jul 16.

PMID:
30012853
5.

Engaging Anaphase Catastrophe Mechanisms to Eradicate Aneuploid Cancers.

Kawakami M, Mustachio LM, Liu X, Dmitrovsky E.

Mol Cancer Ther. 2018 Apr;17(4):724-731. doi: 10.1158/1535-7163.MCT-17-1108. Epub 2018 Mar 20. Review.

6.

Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers.

Kawakami M, Mustachio LM, Zheng L, Chen Y, Rodriguez-Canales J, Mino B, Kurie JM, Roszik J, Villalobos PA, Thu KL, Silvester J, Cescon DW, Wistuba II, Mak TW, Liu X, Dmitrovsky E.

Proc Natl Acad Sci U S A. 2018 Feb 20;115(8):1913-1918. doi: 10.1073/pnas.1719760115. Epub 2018 Feb 6.

7.

Evidence for the ISG15-Specific Deubiquitinase USP18 as an Antineoplastic Target.

Mustachio LM, Lu Y, Kawakami M, Roszik J, Freemantle SJ, Liu X, Dmitrovsky E.

Cancer Res. 2018 Feb 1;78(3):587-592. doi: 10.1158/0008-5472.CAN-17-1752. Epub 2018 Jan 17. Review.

8.

G0S2 represses PI3K/mTOR signaling and increases sensitivity to PI3K/mTOR pathway inhibitors in breast cancer.

Yim CY, Bikorimana E, Khan E, Warzecha JM, Shin L, Rodriguez J, Dmitrovsky E, Freemantle SJ, Spinella MJ.

Cell Cycle. 2017;16(21):2146-2155. doi: 10.1080/15384101.2017.1371884. Epub 2017 Sep 14.

9.

Reply to "Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non-Small Cell Lung Cancer: Methodological Issues".

Sepesi B, Correa AM, Dmitrovsky E, Liu X.

J Thorac Oncol. 2017 Sep;12(9):e150-e151. doi: 10.1016/j.jtho.2017.07.003. No abstract available.

10.

The Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non-Small Cell Lung Cancer.

Sepesi B, Gold KA, Correa AM, Heymach JV, Vaporciyan AA, Roszik J, Dmitrovsky E, Liu X.

J Thorac Oncol. 2017 Aug;12(8):1280-1287. doi: 10.1016/j.jtho.2017.05.010. Epub 2017 May 25.

11.

Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer.

Kawakami M, Mustachio LM, Rodriguez-Canales J, Mino B, Roszik J, Tong P, Wang J, Lee JJ, Myung JH, Heymach JV, Johnson FM, Hong S, Zheng L, Hu S, Villalobos PA, Behrens C, Wistuba I, Freemantle S, Liu X, Dmitrovsky E.

J Natl Cancer Inst. 2017 Jun 1;109(6). doi: 10.1093/jnci/djw297.

12.

Deubiquitinase USP18 Loss Mislocalizes and Destabilizes KRAS in Lung Cancer.

Mustachio LM, Lu Y, Tafe LJ, Memoli V, Rodriguez-Canales J, Mino B, Villalobos PA, Wistuba I, Katayama H, Hanash SM, Roszik J, Kawakami M, Cho KJ, Hancock JF, Chinyengetere F, Hu S, Liu X, Freemantle SJ, Dmitrovsky E.

Mol Cancer Res. 2017 Jul;15(7):905-914. doi: 10.1158/1541-7786.MCR-16-0369. Epub 2017 Feb 27.

13.

The ISG15-specific protease USP18 regulates stability of PTEN.

Mustachio LM, Kawakami M, Lu Y, Rodriguez-Canales J, Mino B, Behrens C, Wistuba I, Bota-Rabassedas N, Yu J, Lee JJ, Roszik J, Zheng L, Liu X, Freemantle SJ, Dmitrovsky E.

Oncotarget. 2017 Jan 3;8(1):3-14. doi: 10.18632/oncotarget.13914.

14.

Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2.

Danilov AV, Hu S, Orr B, Godek K, Mustachio LM, Sekula D, Liu X, Kawakami M, Johnson FM, Compton DA, Freemantle SJ, Dmitrovsky E.

Mol Cancer Ther. 2016 Nov;15(11):2758-2766. Epub 2016 Aug 22.

15.

Retinoids and rexinoids in cancer prevention: from laboratory to clinic.

Uray IP, Dmitrovsky E, Brown PH.

Semin Oncol. 2016 Feb;43(1):49-64. doi: 10.1053/j.seminoncol.2015.09.002. Epub 2015 Sep 25. Review.

16.

G0S2 Suppresses Oncogenic Transformation by Repressing a MYC-Regulated Transcriptional Program.

Yim CY, Sekula DJ, Hever-Jardine MP, Liu X, Warzecha JM, Tam J, Freemantle SJ, Dmitrovsky E, Spinella MJ.

Cancer Res. 2016 Mar 1;76(5):1204-13. doi: 10.1158/0008-5472.CAN-15-2265. Epub 2016 Feb 2.

17.

Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas.

Chinyengetere F, Sekula DJ, Lu Y, Giustini AJ, Sanglikar A, Kawakami M, Ma T, Burkett SS, Eisenberg BL, Wells WA, Hoopes PJ, Demicco EG, Lazar AJ, Torres KE, Memoli V, Freemantle SJ, Dmitrovsky E.

BMC Cancer. 2015 Nov 10;15:886. doi: 10.1186/s12885-015-1883-8.

18.

Effective capture of circulating tumor cells from a transgenic mouse lung cancer model using dendrimer surfaces immobilized with anti-EGFR.

Myung JH, Roengvoraphoj M, Tam KA, Ma T, Memoli VA, Dmitrovsky E, Freemantle SJ, Hong S.

Anal Chem. 2015 Oct 6;87(19):10096-102. doi: 10.1021/acs.analchem.5b02766. Epub 2015 Sep 10.

19.

Specific CP110 Phosphorylation Sites Mediate Anaphase Catastrophe after CDK2 Inhibition: Evidence for Cooperation with USP33 Knockdown.

Hu S, Lu Y, Orr B, Godek K, Mustachio LM, Kawakami M, Sekula D, Compton DA, Freemantle S, Dmitrovsky E.

Mol Cancer Ther. 2015 Nov;14(11):2576-85. doi: 10.1158/1535-7163.MCT-15-0443. Epub 2015 Aug 24.

20.

The Myb-p300 Interaction Is a Novel Molecular Pharmacologic Target.

Liu X, Gold KA, Dmitrovsky E.

Mol Cancer Ther. 2015 Jun;14(6):1273-5. doi: 10.1158/1535-7163.MCT-15-0271. Epub 2015 May 20. No abstract available.

21.

CDK2 Inhibition Causes Anaphase Catastrophe in Lung Cancer through the Centrosomal Protein CP110.

Hu S, Danilov AV, Godek K, Orr B, Tafe LJ, Rodriguez-Canales J, Behrens C, Mino B, Moran CA, Memoli VA, Mustachio LM, Galimberti F, Ravi S, DeCastro A, Lu Y, Sekula D, Andrew AS, Wistuba II, Freemantle S, Compton DA, Dmitrovsky E.

Cancer Res. 2015 May 15;75(10):2029-38. doi: 10.1158/0008-5472.CAN-14-1494. Epub 2015 Mar 25.

22.

MCL1 enhances the survival of CD8+ memory T Cells after viral infection.

Gui J, Hu Z, Tsai CY, Ma T, Song Y, Morales A, Huang LH, Dmitrovsky E, Craig RW, Usherwood EJ.

J Virol. 2015 Feb;89(4):2405-14. doi: 10.1128/JVI.02480-14. Epub 2014 Dec 10.

23.

Mice lacking G0S2 are lean and cold-tolerant.

Ma T, Lopez-Aguiar AG, Li A, Lu Y, Sekula D, Nattie EE, Freemantle S, Dmitrovsky E.

Cancer Biol Ther. 2014 May;15(5):643-50. doi: 10.4161/cbt.28251. Epub 2014 Feb 20.

24.

All-trans-retinoic acid antagonizes the Hedgehog pathway by inducing patched.

Busch AM, Galimberti F, Nehls KE, Roengvoraphoj M, Sekula D, Li B, Guo Y, Direnzo J, Fiering SN, Spinella MJ, Robbins DJ, Memoli VA, Freemantle SJ, Dmitrovsky E.

Cancer Biol Ther. 2014 Apr;15(4):463-72. doi: 10.4161/cbt.27821. Epub 2014 Feb 4.

25.

Inhibiting retinoic acid signaling ameliorates graft-versus-host disease by modifying T-cell differentiation and intestinal migration.

Aoyama K, Saha A, Tolar J, Riddle MJ, Veenstra RG, Taylor PA, Blomhoff R, Panoskaltsis-Mortari A, Klebanoff CA, Socié G, Munn DH, Murphy WJ, Serody JS, Fulton LM, Teshima T, Chandraratna RA, Dmitrovsky E, Guo Y, Noelle RJ, Blazar BR.

Blood. 2013 Sep 19;122(12):2125-34. doi: 10.1182/blood-2012-11-470252. Epub 2013 Jun 27.

26.

Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer.

Ma T, Galimberti F, Erkmen CP, Memoli V, Chinyengetere F, Sempere L, Beumer JH, Anyang BN, Nugent W, Johnstone D, Tsongalis GJ, Kurie JM, Li H, Direnzo J, Guo Y, Freemantle SJ, Dragnev KH, Dmitrovsky E.

Mol Cancer Ther. 2013 Aug;12(8):1545-55. doi: 10.1158/1535-7163.MCT-12-0933. Epub 2013 May 16.

27.

Evidence for tankyrases as antineoplastic targets in lung cancer.

Busch AM, Johnson KC, Stan RV, Sanglikar A, Ahmed Y, Dmitrovsky E, Freemantle SJ.

BMC Cancer. 2013 Apr 28;13:211. doi: 10.1186/1471-2407-13-211.

28.

Repression of exogenous gene expression by the retinoic acid target gene G0S2.

Ma T, Dong JP, Sekula DJ, Fei DL, Lamph WW, Henderson M, Lu Y, Blumen S, Freemantle SJ, Dmitrovsky E.

Int J Oncol. 2013 May;42(5):1743-53. doi: 10.3892/ijo.2013.1876. Epub 2013 Mar 28.

29.

A phase I trial and in vitro studies combining ABT-751 with carboplatin in previously treated non-small cell lung cancer patients.

Ma T, Fuld AD, Rigas JR, Hagey AE, Gordon GB, Dmitrovsky E, Dragnev KH.

Chemotherapy. 2012;58(4):321-9. doi: 10.1159/000343165. Epub 2012 Nov 12.

30.

Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations.

Galimberti F, Busch AM, Chinyengetere F, Ma T, Sekula D, Memoli VA, Dragnev KH, Liu F, Johnson KC, Guo Y, Freemantle SJ, Andrew AS, Greninger P, Robbins DJ, Settleman J, Benes C, Dmitrovsky E.

Int J Oncol. 2012 Nov;41(5):1751-61. doi: 10.3892/ijo.2012.1599. Epub 2012 Aug 22.

31.

A retinoic acid--rich tumor microenvironment provides clonal survival cues for tumor-specific CD8(+) T cells.

Guo Y, Pino-Lagos K, Ahonen CA, Bennett KA, Wang J, Napoli JL, Blomhoff R, Sockanathan S, Chandraratna RA, Dmitrovsky E, Turk MJ, Noelle RJ.

Cancer Res. 2012 Oct 15;72(20):5230-9. doi: 10.1158/0008-5472.CAN-12-1727. Epub 2012 Aug 17.

32.

Evidence for the ubiquitin protease UBP43 as an antineoplastic target.

Guo Y, Chinyengetere F, Dolinko AV, Lopez-Aguiar A, Lu Y, Galimberti F, Ma T, Feng Q, Sekula D, Freemantle SJ, Andrew AS, Memoli V, Dmitrovsky E.

Mol Cancer Ther. 2012 Sep;11(9):1968-77. doi: 10.1158/1535-7163.MCT-12-0248. Epub 2012 Jul 2.

33.

The hedgehog processing pathway is required for NSCLC growth and survival.

Rodriguez-Blanco J, Schilling NS, Tokhunts R, Giambelli C, Long J, Liang Fei D, Singh S, Black KE, Wang Z, Galimberti F, Bejarano PA, Elliot S, Glassberg MK, Nguyen DM, Lockwood WW, Lam WL, Dmitrovsky E, Capobianco AJ, Robbins DJ.

Oncogene. 2013 May 2;32(18):2335-45. doi: 10.1038/onc.2012.243. Epub 2012 Jun 25.

34.

A retinoic acid-dependent checkpoint in the development of CD4+ T cell-mediated immunity.

Pino-Lagos K, Guo Y, Brown C, Alexander MP, Elgueta R, Bennett KA, De Vries V, Nowak E, Blomhoff R, Sockanathan S, Chandraratna RA, Dmitrovsky E, Noelle RJ.

J Exp Med. 2011 Aug 29;208(9):1767-75. doi: 10.1084/jem.20102358. Epub 2011 Aug 22.

35.

Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.

Dragnev KH, Ma T, Cyrus J, Galimberti F, Memoli V, Busch AM, Tsongalis GJ, Seltzer M, Johnstone D, Erkmen CP, Nugent W, Rigas JR, Liu X, Freemantle SJ, Kurie JM, Waxman S, Dmitrovsky E.

Cancer Prev Res (Phila). 2011 Jun;4(6):818-28. doi: 10.1158/1940-6207.CAPR-10-0376.

36.

Hedgehog-producing cancer cells respond to and require autocrine Hedgehog activity.

Singh S, Wang Z, Liang Fei D, Black KE, Goetz JA, Tokhunts R, Giambelli C, Rodriguez-Blanco J, Long J, Lee E, Briegel KJ, Bejarano PA, Dmitrovsky E, Capobianco AJ, Robbins DJ.

Cancer Res. 2011 Jul 1;71(13):4454-63. doi: 10.1158/0008-5472.CAN-10-2313. Epub 2011 May 12.

37.

Involvement of microRNAs in lung cancer biology and therapy.

Liu X, Sempere LF, Guo Y, Korc M, Kauppinen S, Freemantle SJ, Dmitrovsky E.

Transl Res. 2011 Apr;157(4):200-8. doi: 10.1016/j.trsl.2011.01.001. Epub 2011 Feb 4. Review.

38.

Anaphase catastrophe is a target for cancer therapy.

Galimberti F, Thompson SL, Ravi S, Compton DA, Dmitrovsky E.

Clin Cancer Res. 2011 Mar 15;17(6):1218-22. doi: 10.1158/1078-0432.CCR-10-1178. Epub 2011 Feb 2.

39.

Cyclin E transgenic mice: discovery tools for lung cancer biology, therapy, and prevention.

Freemantle SJ, Dmitrovsky E.

Cancer Prev Res (Phila). 2010 Dec;3(12):1513-8. doi: 10.1158/1940-6207.CAPR-10-0297. Review.

40.

Blockade of the ubiquitin protease UBP43 destabilizes transcription factor PML/RARα and inhibits the growth of acute promyelocytic leukemia.

Guo Y, Dolinko AV, Chinyengetere F, Stanton B, Bomberger JM, Demidenko E, Zhou DC, Gallagher R, Ma T, Galimberti F, Liu X, Sekula D, Freemantle S, Dmitrovsky E.

Cancer Res. 2010 Dec 1;70(23):9875-85. doi: 10.1158/0008-5472.CAN-10-1100. Epub 2010 Oct 8.

41.

MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors.

Liu X, Sempere LF, Ouyang H, Memoli VA, Andrew AS, Luo Y, Demidenko E, Korc M, Shi W, Preis M, Dragnev KH, Li H, Direnzo J, Bak M, Freemantle SJ, Kauppinen S, Dmitrovsky E.

J Clin Invest. 2010 Apr;120(4):1298-309. doi: 10.1172/JCI39566. Epub 2010 Mar 8.

42.

Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe.

Galimberti F, Thompson SL, Liu X, Li H, Memoli V, Green SR, DiRenzo J, Greninger P, Sharma SV, Settleman J, Compton DA, Dmitrovsky E.

Clin Cancer Res. 2010 Jan 1;16(1):109-20. doi: 10.1158/1078-0432.CCR-09-2151. Epub 2009 Dec 22.

43.

High DNA methyltransferase 3B expression mediates 5-aza-deoxycytidine hypersensitivity in testicular germ cell tumors.

Beyrouthy MJ, Garner KM, Hever MP, Freemantle SJ, Eastman A, Dmitrovsky E, Spinella MJ.

Cancer Res. 2009 Dec 15;69(24):9360-6. doi: 10.1158/0008-5472.CAN-09-1490.

44.

Wnt pathway reprogramming during human embryonal carcinoma differentiation and potential for therapeutic targeting.

Snow GE, Kasper AC, Busch AM, Schwarz E, Ewings KE, Bee T, Spinella MJ, Dmitrovsky E, Freemantle SJ.

BMC Cancer. 2009 Oct 29;9:383. doi: 10.1186/1471-2407-9-383.

45.

Tumor-suppressive microRNAs in Lung cancer: diagnostic and therapeutic opportunities.

Sempere LF, Liu X, Dmitrovsky E.

ScientificWorldJournal. 2009 Jul 13;9:626-8. doi: 10.1100/tsw.2009.88.

46.

Uncovering growth-suppressive MicroRNAs in lung cancer.

Liu X, Sempere LF, Galimberti F, Freemantle SJ, Black C, Dragnev KH, Ma Y, Fiering S, Memoli V, Li H, DiRenzo J, Korc M, Cole CN, Bak M, Kauppinen S, Dmitrovsky E.

Clin Cancer Res. 2009 Feb 15;15(4):1177-83. doi: 10.1158/1078-0432.CCR-08-1355.

47.

Retinoid chemoprevention trials: cyclin D1 in the crosshairs.

Freemantle SJ, Guo Y, Dmitrovsky E.

Cancer Prev Res (Phila). 2009 Jan;2(1):3-6. doi: 10.1158/1940-6207.CAPR-08-0218. Review. No abstract available.

48.

UBE1L causes lung cancer growth suppression by targeting cyclin D1.

Feng Q, Sekula D, Guo Y, Liu X, Black CC, Galimberti F, Shah SJ, Sempere LF, Memoli V, Andersen JB, Hassel BA, Dragnev K, Dmitrovsky E.

Mol Cancer Ther. 2008 Dec;7(12):3780-8. doi: 10.1158/1535-7163.MCT-08-0753.

49.

G0S2 is an all-trans-retinoic acid target gene.

Kitareewan S, Blumen S, Sekula D, Bissonnette RP, Lamph WW, Cui Q, Gallagher R, Dmitrovsky E.

Int J Oncol. 2008 Aug;33(2):397-404.

50.

The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis.

Liby K, Black CC, Royce DB, Williams CR, Risingsong R, Yore MM, Liu X, Honda T, Gribble GW, Lamph WW, Sporn TA, Dmitrovsky E, Sporn MB.

Mol Cancer Ther. 2008 May;7(5):1251-7. doi: 10.1158/1535-7163.MCT-08-0023.

Supplemental Content

Loading ...
Support Center